| Bioactivity | Levobunolol (l-Bunolol) is a potent and nonselective β-adrenergic receptor antagonist. Levobunolol is an ocular hypotensive agent and lowers mean intraocular pressure (IOP). Levobunolol can be used for glaucoma and superior oblique myokymia (SOM) research[1][2][3]. |
| Name | Levobunolol |
| CAS | 47141-42-4 |
| Formula | C17H25NO3 |
| Molar Mass | 291.39 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mohammadi M, et al. Injectable drug depot engineered to release multiple ophthalmic therapeutic agents with precise time profiles for postoperative treatment following ocular surgery. Acta Biomater. 2018 Jun;73:90-102. [2]. Kumar, N, et al. Extended levobunolol release from Eudragit nanoparticle-laden contact lenses for glaucoma therapy. Futur J Pharm Sci 6, 109 (2020). [3]. Zhang M, et al. Superior oblique myokymia treated with levobunolol. J AAPOS. 2018 Feb;22(1):67-69.e2. |
Levobunolol
CAS: 47141-42-4 F: C17H25NO3 W: 291.39
Levobunolol (l-Bunolol) is a potent and nonselective β-adrenergic receptor antagonist. Levobunolol is an ocular hypoten
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.